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Abstract
Background: Cross-sectional surveys utilizing biomarkers that test for recent infection provide a convenient and cost
effective way to estimate HIV incidence. In particular, the BED assay has been developed for this purpose. Controversy
surrounding the way in which false positive results from the biomarker should be handled has lead to a number of different
estimators that account for imperfect specificity. We compare the estimators proposed by McDougal et al., Hargrove et al.
and McWalter & Welte.
Methodology/Principal Findings: The three estimators are analyzed and compared. An identity showing a relationship
between the calibration parameters in the McDougal methodology is shown. When the three estimators are tested under a
steady state epidemic, which includes individuals who fail to progress on the biomarker, only the McWalter/Welte method
recovers an unbiased result.
Conclusions/Significance: Our analysis shows that the McDougal estimator can be reduced to a formula that only requires
calibration of a mean window period and a long-term specificity. This allows simpler calibration techniques to be used and
shows that all three estimators can be expressed using the same set of parameters. The McWalter/Welte method is
applicable under the least restrictive assumptions and is the least prone to bias of the methods reviewed.
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Introduction
Although prospective follow-up of an initially HIV-negative
cohort is widely regarded as the ‘‘gold-standard’’ for estimating
incidence, the idea of utilizing a biomarker to define a suitable
class of ‘‘recently infected’’ individuals, and then to use the
prevalence of this class as the basis for estimating HIV incidence, is
attractive for a number of reasons. Since this can be implemented
using a cross-sectional survey, it is logistically simpler, cheaper and
less prone to the biases that result from intervention and loss to
follow-up.
The BED capture enzyme immunoassay (BED assay) has been
developed for this purpose [1,2] and widely used [3]. It measures
the proportion of IgG that is HIV-1 specific as a normalized
optical density (ODn). Since this proportion increases over time
after the infection event, specifying an ODn threshold allows
seropositive individuals to be classified as recently infected, if they
are below threshold, and as non-recently infected, if they are
above threshold. Initially, an incidence formula was proposed [1]
that did not explicitly account for the possibility of assay non-
progressors (i.e. individuals who never develop enough of an
immunological response to cross the threshold). This method was
similar to the earlier approaches of Brookmeyer and Quinn [4],
and Janssen et al. [5]. Later, the methodology proposed by
McDougal et al. [6] was the first to deal with assay non-progressors.
They derived an incidence formula which can be expressed in
terms of the prevalence of below-threshold seropositive, above-
threshold seropositive and seronegative individuals, and four assay
calibration parameters, being the mean window period (v),
sensitivity (s), short-term specificity (r1) and long-term specificity
(r2). Introducing the long-term specificity parameter provided a
way to quantify assay non-progression.
Two other incidence paradigms that explicitly account for assay
non-progressors have since been formulated. Hargrove et al. [7]
proposed a simpler incidence estimator which is equivalent to the
McDougal estimator when one sets s~r1. Recently, we have also
proposed a formally rigorous incidence paradigm [8], which
accounts for assay non-progression using fewer assumptions than
are made by McDougal et al. The parameters that emerge
naturally in our estimator are a mean window period and a
probability of not progressing on the assay (which can also be
expressed as a long-term specificity).
A large portion of this paper is dedicated to an analysis of the
assay parameters of the McDougal methodology, showing how
they are related. By using a survival analysis formulation of the
problem, we are able to write down precise expressions for the
parameters. This allows us to derive a relationship between three
of the parameters, which simplifies the McDougal estimator by
showing that only v and r2, which are considerably easier to
calibrate than s and r1, are required in the final formula. The
reduction of the McDougal approach is important in that it shows
that all three incidence estimators are, in effect, based on the same
underlying parameters characterising the performance of the
assay, and are therefore amenable to direct comparison.
We then compare the performance of the three incidence
estimators by substituting analytic expressions for population
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counts, derived from a model steady state epidemic, into the
various formulae. This analysis shows that only our formula [8]
produces a bias-free result. Although the biases are typically small,
we demonstrate, using numerical examples, that there are regimes
where bias may be significant.
The paper is structured as follows: We start by describing the
McDougal methodology and, in doing so, write down mathemat-
ical expressions for the assay calibration parameters. In the next
section we restate the assumptions made by McDougal et al. in a
mathematically precise manner. This allows us to derive the
identity that shows the relationship between the parameters. We
then present the three incidence formulae and compare them by
inserting the population counts from a model steady state
epidemic. We conclude the paper with a discussion of the
implications of the identity and the steady state analysis.
Analysis
The McDougal Methodology
Denote the number of individuals in a cross-sectional sample
who are respectively under-threshold, over-threshold and healthy
(susceptible) by NU, NO and NH. Then the McDougal estimator
[6] can be written as
I~
fNU
fNUzvNH
, ð1Þ
where v is specified in years and the ‘‘correction factor’’,
f :~
Pt
Po
~
Pozr2{1
Po s{r1z2r2{1ð Þ
, ð2Þ
is the ratio of the ‘‘true’’ proportion Pt of recent infections and the
proportion Po~NU= NUzNOð Þ of the HIV positive individuals
that are under the threshold. This correction factor, which
depends on subtle definitions for the sensitivity and specificity
parameters, explicitly accounts for the fact that the BED assay
imperfectly classifies individuals as ‘‘recently infected’’.
McDougal et al. calibrate these parameters using seroconversion
panels which show BED optical density as a function of time since
infection (some of these are published [1,2]). The calibration
occurs in two stages. A window period is estimated, and then
estimates of the sensitivity, short-term specificity and long-term
specificity are determined with respect to the window period.
The window period is estimated as ‘‘the mean period of time
from initial seroconversion to reaching an ODn of 0.8’’ [6].
Although it is not explicitly stated, we presume that those
individuals that never reach the threshold, either because they
do not progress above the threshold or because they die before
reaching the threshold, are not included in the calculation of the
mean. More specifically this implies that the window period is the
mean observable threshold crossing time, conditional on assay
progression (i.e. actually reaching the threshold).
In order to calibrate the sensitivity, short-term specificity and
long-term specificity, ‘‘a plot of the proportion of specimens positive
in the assay versus time since seroconversion’’ is generated (also later
referred to as ‘‘the curve’’). This is the sampled survival function
(essentially a Kaplan-Meier curve) in the state of being under the
threshold, conditional on being alive, which we denote SUjA tð Þ.
The sensitivity of the test is estimated for an interval
corresponding to the window period by ‘‘integrating the curve
within the window’’. Short-term specificity is calculated for ‘‘the
interval immediately after, and equal in duration to, the window
period’’. Long-term specificity is for ‘‘the period thereafter (where
the curve is flat)’’. McDougal et al. explicitly make the following
assumptions, with the justification that they ‘‘are reasonable as
very little attrition (from death) during the first two time intervals
after infection would be expected’’:
1. ‘‘Recent infections are randomly distributed within the first
window period’’.
2. ‘‘The number of persons in the interval of equal duration
immediately after the mean window period equals the number
in the first window period’’.
3. ‘‘The remainder of the population is more than two window
periods since seroconversion’’.
While it may be true in the situation being explored here, we note
that it is not a priori obvious that the choice of equal window periods
ensures that SUjA tð Þ is flat after twice the window period. With this
in mind, we propose a generalization in which there are two window
periods with arbitrary values v1 and v2, chosen so that all
individuals that progress do so in a time less than v1zv2 after
seroconversion (i.e. SUjA tð Þ is flat for twv1zv2, see the bottom
graph of Figure 1). It should be noted that this is a special survival
curve in that it never reaches a zero value, capturing the fact that a
certain proportion of individuals will never progress above the
threshold. This is what differentiates this approach from other
approaches that do not account for assay non-progression (Such as
Brookmeyer and Quinn [4], Janssen et al. [5], and Parekh et al. [1]).
For analytical convenience, we introduce SPUjA tð Þ, the survival
of assay progressors in the state of being under-threshold. We also
introduce RNP, the probability of individuals not progressing on the
assay. Then SUjA tð Þ, SPUjA tð Þ and RNP are related by
SUjA tð Þ~ 1{RNPð ÞSPUjA tð ÞzRNP:
The introduction of SPUjA tð Þ allows us to provide a precise
definition of the window period used by McDougal et al. It is the
mean time between seroconversion and reaching threshold, for
individuals who progress:
v~
ð?
0
SPUjA tð Þ dt: ð3Þ
Assumption 1 above can only mean that infection times in the
first window period are uniformly distributed. Although assumption 2
merely states that the number of infections in the second window
period is equal to the number in the first, we shall see later that for
r1 to be a property of the assay, independent of the epidemic state,
we require the stronger assumption that the infection events in the
second window period are also uniformly distributed with the same
intensity as in the first window period. We see below that this
assumption is implicit in the work of McDougal et al. To make this
more explicit, we define f tð Þ to be the density of times since
infection realized in the sample. The number of seropositive
individuals is then given by
Nsp~
X6
i~1
ni~
ð?
0
f tð Þ dt,
where ni are the counts of individuals in the various categories
depicted in the top graph in Figure 1.
Setting f tð Þ~f0 over the first two window periods means that the
ratio of the number of infected individuals in the second window
Biomarker Incidence Estimators
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period to those in the first period is v2=v1. Assumption 2 is
recovered when the length of the window periods is equal. It should
be noted that f tð Þ depends on incidence, susceptible population and
life expectancies over the history of the epidemic. With reference to
Figure 1, we are now in a position to write expressions for the
number of seropositive individuals in each sector:
n1~
ðv1
0
f tð Þ 1{SUjA tð Þ
 
dt~f0 1{RNPð Þ
ðv1
0
1{SPUjA tð Þ
 
dt
n2~
ðv1
0
f tð ÞSUjA tð Þ dt~f0v1RNPzf0 1{RNPð Þ
ðv1
0
SPUjA tð Þ dt
n3~
ðv1zv2
v1
f tð Þ 1{SUjA tð Þ
 
dt~f0 1{RNPð Þ
ðv1zv2
v1
1{SPUjA tð Þ
 
dt
n4~
ðv1zv2
v1
f tð ÞSUjA tð Þdt~f0v2RNPzf0 1{RNPð Þ
ðv1zv2
v1
SPUjA tð Þdt
n5~
ð?
v1zv2
f tð Þ 1{SUjA tð Þ
 
dt~ 1{RNPð Þ
ð?
v1zv2
f tð Þ dt
n6~
ð?
v1zv2
f tð ÞSUjA tð Þ dt~RNP
ð?
v1zv2
f tð Þ dt:
Using the above expressions, the sensitivity, the short-term
specificity and the long-term specificity are given by
s~
n2
n1zn2
~
1{RNPð Þ
Ðv1
0
SPUjA tð Þ dtzv1RNP
v1
r1~
n3
n3zn4
~
1{RNPð Þ
Ðv1zv2
v1
1{SPUjA tð Þ
 
dt
v2
r2~
n5
n5zn6
~1{RNP:
We can now see why the assumption of uniformly distributed
infection events for the first and second window periods is required
– it is the only way in which a cancelation of f tð Þ in the
expressions for s and r1 is possible. Note that under bias-free
Figure 1. The six sector model of McDougal et al. The top graph shows counts ni and the bottom graph shows the survival function SUjA tð Þ
versus time since infection.
doi:10.1371/journal.pone.0007368.g001
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recruitment into a survey, at time t~0, we have
f tð Þ~Nsp
Tsp
I {tð ÞH {tð ÞSA tð Þ, ð4Þ
where I tð Þ is the instantaneous incidence, H tð Þ is the number of
healthy (susceptible) individuals, SA tð Þ is the life-expectancy
survival function measured from the time since infection and
Tsp~
ð?
0
I {tð ÞH {tð ÞSA tð Þ dt
is the total number of seropositive individuals alive in the
population at the time of the survey. The ratio Nsp

Tsp is just
the fraction of the total population that has been recruited. Thus,
the only sensible way to ensure that f tð Þ~f0 for tƒv1zv2, is to
assume that the incidence and the susceptible population are
constant, and the survival function SA tð Þ~SA 0ð Þ~1.
We also see why SUjA tð Þ must be flat after both window periods
– this ensures that SUjA tð Þ is constant and can be pulled out of the
integrals in the expressions for n5 and n6 as the factor RNP. This is
necessary for r2 to be independent of f tð Þ.
Furthermore, in order to specify r2 so that it is independent of
the state of the epidemic, an implicit assumption is being made
that survival is the same for assay progressors and assay non-
progressors. Note that f tð Þ appears in the expressions for both n5
and n6. If different life expectancies were used in these formulae,
reflecting a difference in survival for assay progressors and assay
non-progressors, the f 9s in these formulae would need to be
different, and would not cancel in the expression for r2. This
assumption is not explicitly stated by McDougal et al. but is implicit
in their assumption that r2 is independent of epidemic state.
With the calibration parameters specified in the more general
setting of unequal window periods v1 and v2, we now generalize
the expression for the correction factor
f~
Pt
Po
,
where Pt~ n1zn2ð Þ

Nsp is the proportion of seropositive
individuals who are truly infected at a time less than v1. Recalling
that Po~ n2zn4zn6ð Þ

Nsp and using the definitions of the
parameters, it is easy to verify that
Po~PtszPt
v2
v1
1{r1ð Þz 1{Pt{Pt
v2
v1
 
1{r2ð Þ:
This means that the correction factor can be expressed as
f~
Pozr2{1
Po s{
v2
v1
r1z 1z
v2
v1
 
r2{1
h i : ð5Þ
Note that this equation simplifies to the previous expression (2)
when one sets v1~v2.
Elimination of Parameters
For completeness, we now provide a precise specification of the
assumptions that are required in order to facilitate the analysis in
the rest of this paper. We note that with the exception of arbitrary
sized window periods, these assumptions are equivalent to the
assumptions – either explicit or implicit – that are being made by
McDougal et al. [6].
Model Assumptions. Specify window periods v1 and v2. We
assume that:
1. The window periods are chosen so that the survival function SUjA tð Þ is
flat (and equal to RNP) for twv1zv2 . This means that SPUjA tð Þ
only has support on the time interval t [ 0,v1zv2½  .
2. Arrival times of infection events are uniformly distributed on the interval
0,v1zv2½ . An equivalent way of stating this assumption is that over the
interval t [ 0,v1zv2½ ; H tð Þ and I tð Þ are constant and SA tð Þ~1.
3. Survival is the same for assay progressors and assay non-progressors.
We are now able to provide the identity relating the parameters
in the McDougal approach.
Proposition 1. Under the model assumptions stated above, the
following identity holds:
s{
v2
v1
r1z 1z
v2
v1
{
v
v1
 
r2~1: ð6Þ
Proof. Since we assume that SPUjA tð Þ only has support on
t [ 0,v1zv2½ , we have
ðv1zv2
0
SPUjA tð Þ dt~
ð?
0
SPUjA tð Þ dt~v
Then, simply evaluating
s{
v2
v1
r1~
1{RNPð Þ
Ðv1
0 SPUjA tð Þ dtzv1RNP
v1
{
v2
v1
1{RNPð Þ
Ðv1zv2
v1
1{SPUjA tð Þ
 
dt
v2
~
1{RNPð Þ
Ðv1zv2
0 SPUjA tð Þ dt{
Ðv1zv2
v1
1{RNPð Þ dtzv1RNP
v1
~
1{RNPð Þ v{v2{v1ð Þzv1
v1
~1{ 1z
v2
v1
{
v
v1
 
r2,
yields the result directly.
Using the proposition, the correction factor (5) simplifies to
f~
v1
v
Pozr2{1
Por2
:
This expression no longer relies on estimates for s and r1.
It is also interesting to note that it does not depend explicitly on
v2. Calibrating r2, however, requires identifying individuals
who have been infected for at least v1zv2. Thus, v2 need not
be precisely known, but a safe upper bound for v1zv2 is
required.
Furthermore, if we set v1~v as in McDougal et al. then we
recover
Biomarker Incidence Estimators
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f~
Pozr2{1
Por2
: ð7Þ
Note that (2) as stated in McDougal et al. contains three calibration
parameters (s, r1 and r2), while (7) contains only one calibration
parameter (r2). Incidence estimates using (1) and (7), however, still
require the estimation of v. The method of McDougal et al. can in
principle be applied to an arbitrarily declared (as opposed to
measured) window period, as long as s, r1 and r2 are calibrated
for that value. We have therefore reduced the number of
calibration parameters by one.
Estimation of extra parameters may unnecessarily dilute the
statistical power of the calibration data at hand. Moreover,
estimates of the uncertainty due to calibration, based on the
assumption of the independence of s, r1 and r2, will be incorrect.
Note that when one sets v1~v2~v, the identity is reduced to
s{r1zr2~1:
Substituting the estimates of the parameters found by
McDougal et al., namely s~0:768, r1~0:723 and r2~0:944,
into this equation gives a value of 0:989&1 for the left hand side.
The slight discrepancy is a manifestation of the combined
fluctuations in the estimates of s, r1, r2 and v. Although v is
superficially absent in the identity, it enters as the period over
which the other parameters are defined.
When one assumes that r2~1 (corresponding to the situation
where there are no assay non-progressors) and v1~v, the identity
reduces to
v 1{sð Þ~v2 1{r1ð Þ ð8Þ
and the ratio of counts over this period is given by
n1zn2
n3zn4
~
v
v2
:
Using this ratio and substituting the definitions for s and r1 into
(8) yields n1~n4. Therefore, for tests with perfect long-term
specificity, the observed count of individuals who are under-
threshold is an unbiased estimate of the number of infections in the
last period v. This was noted in a less general analysis of
Brookmeyer [9] where assay non-progressors were a priori
excluded.
It should be noted that there is a subtlety in the definition of the
window period that emerges in the above analysis. If, instead of (3),
the window period is defined by
v :~
ð?
0
SPUjA tð ÞSA tð Þ dt: ð9Þ
then the two definitions are equivalent under the model
assumptions leading to the proposition. This follows from the fact
that SPUjA tð Þ only has support on t [ 0,v1zv2½  and that
SA tð Þ~1 over that interval. We have suggested an alternative
incidence estimation paradigm [8] which requires fewer assump-
tions than the method of McDougal et al. In this approach RNP and
v, as defined in (9), emerge as the natural calibration parameters.
Comparison of Estimators Under Steady State Conditions
We now provide a simplified form for the McDougal incidence
estimator based on the proposition. Substituting the new
correction factor (7) into their estimator (1) and expressing the
result in terms NU, NO and NH gives
Ia~
NU{RNP NUzNOð Þ
NU{RNP NUzNOð Þzv 1{RNPð ÞNH , ð10Þ
where v is specified in years. Here the subscript a indicates that
the estimator is quoted as an ‘‘annualized incidence’’. Note that in
writing down this expression, we have chosen to use RNP rather
than the long-term specificity as this is a biologically more intuitive
parameter. In addition, the other two estimators to which this
estimator will be compared were originally specified in terms of
RNP.
In a previous attempt to simplify the McDougal formula,
Hargrove et al. [7] proposed the following incidence formula
~Ia~
NU{RNP NUzNOð Þ
NU{RNP NUzNOzNHð ÞzvNH , ð11Þ
where v is specified in years. Note that they use the symbol e
where we use RNP.
We have recently rigorously derived a weighted incidence
estimator under less restrictive assumptions than those that are
required for the McDougal or Hargrove approach [8]. Unlike the
other two estimators, our estimator is expressed as a rate (indicated
by a subscript r) and is given by
I^ r~
NU{
RNP
1{RNP
NO
vNH
~
NU{RNP NUzNOð Þ
v 1{RNPð ÞNH :
ð12Þ
To convert between an annualized incidence and an incidence
expressed as a rate, one can use the standard conversion formula
Ia~1{e
{IrT u Ir~
{ln 1{Iað Þ
T
,
where T~1 year.
In Appendix S1 we show that, under steady state conditions,
NUand NO are specified in terms of NH and an incidence rate I as
NO~INH 1{RNPð Þ a{vð Þ ð13Þ
and
NU~INH 1{RNPð ÞvzINHRNPa ð14Þ
where a is the post-infection life expectancy. Using these
population counts, it is now possible to compare the performance
of the incidence estimators. Substituting (13) and (14) into the
McDougal formula (10) yields
Ia~
I
Iz1
:
Biomarker Incidence Estimators
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Converting this to a rate, we have
Ir~ln Iz1ð Þ~IzO Ið Þ2,
where the last step results from a Taylor series expansion. Thus the
estimator is accurate for small values of I , but yields a discrepancy
at O Ið Þ2. The reason for this discrepancy is subtle. In deriving the
correction factor, McDougal et al. assume uniform infection events
over the window periods. We have shown that this is consistent
with assuming that the incidence and susceptible population are
constant. In using this factor to estimate an incidence with (1) they
have, however, inconsistently assumed that these infection events
are generated in a susceptible population which is being depleted
by the infection events over a period of a year. This is implied by
their choice of denominator in that formula, which adds back an
annualized number of recent infections into the susceptible
population. This is at odds with the assumption of a constant
susceptible population, and leads to dimensionally inconsistent
incidence estimators, (1) and (10).
To illustrate the magnitude of the bias, Figure 2 shows the
difference between the McDougal incidence estimate and the
equilibrium incidence, expressed as a percentage. Note that the
range of incidence values used is large (up to 50% per annum).
Although incidence for HIV is not likely to be larger than about
15% in the highest risk groups (e.g. injection drug users [10]), if
this methodology were used to monitor other rapidly spreading
epidemics, where incidence is large when stated in units of years, it
would certainly produce unacceptable bias.
Substituting the counts into the Hargrove formula (11) yields
~Ia~
I
Iz v{RNP
1{RNPð Þv
,
which, when converted to a rate, gives
~Ir~ln
I 1{RNPð Þv
v{RNP
z1
 
~Iz
RNP 1{vð Þ
v{RNP
IzO I2
 
:
The Hargrove estimator incorporates the same form of denom-
inator which leads to the second order discrepancy and
dimensional inconsistency in the McDougal formula, and, in
addition, it includes a linear bias term. Figure 3 demonstrates the
bias introduced as a function of v and RNP for an equilibrium
incidence of 5% per annum. Although the bias is worst in the
regimes where all the estimators have little statistical power and
are unlikely to be used, there are nevertheless intermediate regimes
where the bias is significant. Note that the estimator produces the
same result (and bias) as the McDougal estimator when RNP~0 or
v~1.
Finally, substituting the counts into our formula (12), which is
already specified as a rate, yields
I^r~I :
Thus, under the assumption of a steady state epidemic, our
weighted incidence estimator recovers the steady state incidence
exactly. It is also the maximum likelihood estimator. This can be
seen by writing the estimator in terms of the population
proportions
I^r~
PU{
RNP
1{RNP
PO
vPH
, where PX~
NX
Nsp
,
and noting that, since the counts are trinomially distributed, the
sample proportions are the maximum likelihood estimates of the
population proportions. We have already seen that the estimator
solves for the equilibrium incidence. Thus, by the invariance
property of maximum likelihood estimators (see e.g. p. 105 of van
den Bos [11]), it is the maximum likelihood estimator for the
incidence. This has also recently been demonstrated by Wang and
Lagakos [12] by explicit maximization of the log likelihood function.
A weighted incidence will in general not be equal to the
instantaneous incidence under non-steady state conditions. We
should, however, demand that any incidence formula exactly
recover the incidence under this rather idealized situation.
Discussion
We have shown that under a precise restatement of the
McDougal et al. assumptions, there exists a redundancy in the
parameters they chose to characterise the assay. This allows the
elimination of s and r1 from their estimator, with the important
advantage that the remaining parameters are easier to calibrate.
The calibration of s and r1 requires obtaining specimens from
individuals with confidence about their time since infection (i.e.
using frequent follow-up). On the other hand both v and RNP (or
equivalently r2) can be estimated through long follow-up intervals.
The estimate for RNP is the proportion of under-threshold samples
known to be obtained more than v1zv2 post-infection. Given an
estimate for RNP, an estimate of v can be obtained from data with
follow-up intervals greater than v1zv2 using an extended version
[13] of the Bayesian approach previously described by Welte [14].
We have also shown that under steady state conditions the only
estimator that is dimensionally consistent and produces an
unbiased result is the one we have previously derived [8]. It is
Figure 2. Bias in the McDougal estimator. Relative difference
between the McDougal estimate and the equilibrium incidence plotted
as a function of equilibrium incidence.
doi:10.1371/journal.pone.0007368.g002
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also the maximum likelihood estimator. The new approach makes
fewer assumptions than the other methods. In particular, it
consistently accounts for a dynamic epidemic by adopting a
weighted definition of incidence. This overcomes a drawback of
the other two methods which assume epidemic equilibrium for at
least a period equal to the maximum progression time (v1zv2). It
should be noted that this methodology is applicable to any
biomarker, not only the BED assay – all that is needed is a suitable
calibration of the assay parameters. It also follows that cross-
sectional incidence estimates using this approach are applicable to
infections other than HIV, as long as suitably calibrated assays that
test for recent infection are available.
A shortcoming of all the methods explored here is that they
make the assumption, either implicitly or explicitly, that survival
for assay non-progressors and assay progressors is the same. As we
have shown, relaxing this assumption means that the long-term
specificity becomes epidemic state dependent and hence is time
dependent. We are involved in ongoing work to address this issue.
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